What to Expect From Viatris' Next Quarterly Earnings Report

Valued at a market cap of $10.8 billion, Viatris Inc. (VTRS) is a healthcare company headquartered in Canonsburg, Pennsylvania. It offers a comprehensive portfolio of brand-name, generic, complex generic, and biosimilar medications across a broad range of therapeutic areas. These include non-communicable and infectious diseases, such as cardiovascular conditions, central nervous system (CNS) disorders, dermatology, diabetes, eye care, gastroenterology, immunology, oncology, and respiratory illnesses.  It is scheduled to announce its fiscal Q2 earnings for 2025 before the market opens on Thursday, Aug. 7.

Before this event, analysts project this healthcare company to report a profit of $0.56 per share, down 18.8% from $0.69 per share in the year-ago quarter. The company has surpassed Wall Street’s bottom-line estimates in three of the last four quarters, while missing on another occasion. Its earnings of $0.50 per share in the previous quarter outpaced the consensus estimates by 2%.